Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Appl Microbiol Biotechnol ; 107(23): 7043-7054, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37741940

RESUMO

Vibrio natriegens is a halophilic bacterium with the fastest generation time of non-pathogenic bacteria reported so far. It therefore has high potential as a production strain for biotechnological production processes or other applications in biotechnology. Culture media for V. natriegens typically contain high sodium chloride concentrations. The corresponding high chloride concentrations can lead to corrosion processes on metal surfaces in bioreactors. Here we report the development of a low-chloride chemically defined medium for V. natriegens. Sodium chloride was completely replaced by the sodium salts disodium hydrogen phosphate, disodium sulfate, and sodium citrate, while keeping the total concentration of sodium ions constant. The use of citrate prevents the occurrence of precipitates, especially of ammonium magnesium phosphate. With this defined medium, high-cell-density fed-batch cultivations in laboratory-scale bioreactors using exponential feeding yielded biomass concentrations of more than 60 g L-1. KEY POINTS: A defined medium for V. natriegens that only contains traces of chloride was developed Corrosion processes on metal surfaces in industrial bioreactors can thus be prevented High yields of biomass can be achieved in fed-batch cultivation with this medium.


Assuntos
Cloretos , Vibrio , Cloretos/farmacologia , Cloreto de Sódio/farmacologia , Reatores Biológicos , Sódio
2.
Med Mycol Case Rep ; 2: 79-84, 2013 Mar 14.
Artigo em Inglês | MEDLINE | ID: mdl-24432223

RESUMO

Mucormycosis is an emergent and threatening invasive fungal invasion underdiagnosed by clinicians due to lack of awareness and aspecific clinical picture. The authors describe a clinical case of a diabetic and cirrhotic patient who developed rhino-orbital-cerebral and pulmonary mucormycosis, non-responsive to treatment. Typical gaps in the management of this deadly disease are addressed. There is a strong need for novel therapies and an expectation that sponsors will recognize the critical need for randomized clinical trials.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA